ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2010-05-18

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-09-1173PMID 20484018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors.

  2016cited by this paper
• Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.

  2010cited by this paper
• MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

  2010cited by this paper
• Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition.

  2009cited by this paper
• Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib.

  2009cited by this paper
• Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.

  2007cited by this paper
• Invasive growth: a MET-driven genetic programme for cancer and stem cells

  2006cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.

  2006cited by this paper
• The MET oncogene drives a genetic programme linking cancer to haemostasis

  2005cited by this paper
• Cancer therapy: can the challenge be MET?

  2005cited by this paper
• c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

  2005cited by this paper
• Targeting the tumor and its microenvironment by a dual-function decoy Met receptor.

  2004cited by this paper
• 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.

  2004cited by this paper
• Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.

  2003cited by this paper
• Oligomerization-induced Modulation of TPR-MET Tyrosine Kinase Activity*

  2003cited by this paper
• Met, metastasis, motility and more

  2003influential reference
• Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.

  2003cited by this paper
• A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

  2003cited by this paper
• Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.

  2003cited by this paper
• K252a inhibits the oncogenic properties of Met, the HGF receptor

  2002cited by this paper
• Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

  2002cited by this paper
• Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

  2001cited by this paper
• Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase

  2001cited by this paper
• A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells.

  2001cited by this paper
• Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.

  2001cited by this paper
• Oncogenic kinase signalling

  2001cited by this paper
• Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells

  2000cited by this paper
• The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

  2000cited by this paper
• The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

  2000cited by this paper
• Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*

  2000cited by this paper
• The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

  1999cited by this paper
• Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor

  1998cited by this paper
• Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase.

  1998cited by this paper
• Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor.

  1997cited by this paper
• Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

  1997cited by this paper
• Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development

  1993cited by this paper
• Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

  1991cited by this paper
• Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

  1991cited by this paper
• Expression of the Met/HGF receptor in normal and neoplastic human tissues.

  1991influential reference
• Evidence for the identity of human scatter factor and human hepatocyte growth factor.

  1991cited by this paper
• Hepatocytes and scatter factor

  1990cited by this paper
• Molecular cloning of a new transforming gene from a chemically transformed human cell line

  1984cited by this paper
• The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001.

  year unknowncited by this paper

• Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning

  2025cites this paper
• Applications of innovative synthetic strategies in anticancer drug Discovery: The Driving Force of new chemical reactions.

  2025cites this paper
• Chemoselective, Dearomative Reduction of Epoxide-Tethered Indoles en Route to HFIP-Promoted Diastereoselective Synthesis of 1,7-Fused Indolines.

  2025cites this paper
• Type X RTKs: HGF (hepatocyte growth factor) receptor family in GtoPdb v.2025.3

  2025cites this paper
• Rational Design, Synthesis, and Biological Evaluation of Novel c-Met Degraders for Lung Cancer Therapy.

  2025cites this paper
• Complex Alkaloid-Type Polycycles via Aza-Michael/Epoxidation of Indole-7-Carbaldehydes with Vinyl Sulfonium Salts and Alkenyl Thianthrenium Salts.

  2025cites this paper
• Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning

  2024cites this paper
• Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth

  2024cites this paper
• Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors.

  2024cites this paper
• Targeted therapies in hepatocellular carcinoma: past, present, and future

  2024cites this paper
• MET receptor serves as a promising target in melanoma brain metastases

  2024cites this paper
• Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling

  2024cites this paper
• Synthesis of 1,7-Fused Indolines Tethered with Spiroindolinone Based on C-H Activation Strategy with Air as a Sustainable Oxidant.

  2024cites this paper
• Papillary Renal Cell Carcinoma: Current Evidence and Future Directions

  2024cites this paper
• Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

  2024cites this paper
• MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  2023cites this paper
• The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis

  2023cites this paper
• Exploring marine-derived compounds for MET signalling pathway inhibition in cancer: integrating virtual screening, ADME profiling and molecular dynamics investigations

  2023cites this paper
• Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy.

  2023cites this paper
• Met inhibitors in the treatment of lung cancer: the evidence to date

  2022cites this paper
• Modulators of Wnt Signaling Pathway Implied in Dentin Pulp Complex Engineering: A Literature Review

  2022cites this paper
• MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression

  2022influential citation
• Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

  2022cites this paper
• Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study

  2022cites this paper
• The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents

  2022cites this paper
• Drug-mediated inhibition of MET activation

  2022cites this paper
• Principles of Kinase Allosteric Inhibition and Pocket Validation.

  2022cites this paper
• Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer

  2022cites this paper
• Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges

  2022cites this paper
• Design, Synthesis, and Evaluation of New Mesenchymal–Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers

  2022cites this paper
• Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy.

  2021cites this paper
• HGF/MET Signalling and DNA Damage Response: Strategies to Conquer Radiotherapy Resistance in Head and Neck Cancer

  2021cites this paper
• Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

  2021cites this paper
• Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis

  2021cites this paper
• The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site

  2021cites this paper
• Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.

  2021cites this paper
• Catalytic Asymmetric C-7 Friedel-Crafts Alkylation/N-Hemiacetalization of 4-Aminoindoles.

  2021cites this paper
• Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future

  2021cites this paper
• Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma

  2021cites this paper
• Drug Repurposing in Dentistry: Towards Application of Small Molecules in Dentin Repair

  2020cites this paper
• Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis

  2020cites this paper
• Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification

  2020cites this paper
• Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors.

  2020cites this paper
• The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents.

  2020cites this paper
• Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review

  2020cites this paper
• Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma

  2020cites this paper
• Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: a Comprehensive Analysis.

  2020cites this paper
• RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

  2020cites this paper
• The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma

  2020cites this paper
• A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

  2020cites this paper
• Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?

  2020influential citation
• HGF/c-Met Axis: The Advanced Development in Digestive System Cancer

  2020cites this paper
• A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma

  2020cites this paper
• Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

  2019cites this paper
• Targeting Cancer from a Structural Biology Perspective

  2019cites this paper
• Cabozantinib for the treatment of hepatocellular carcinoma

  2019cites this paper
• Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma

  2019cites this paper
• Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

  2019cites this paper
• Novel therapy for pediatric and adolescent kidney cancer

  2019cites this paper
• MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines

  2019cites this paper
• Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.

  2019cites this paper
• Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints

  2019cites this paper
• MET Inhibition in Non-Small Cell Lung Cancer

  2019cites this paper
• Investigational MET inhibitors to treat Renal cell carcinoma

  2019cites this paper
• Bispecific Aptamer Induced Artificial Protein-Pairing: A Strategy for Selective Inhibition of Receptor Function.

  2019cites this paper
• Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.

  2019cites this paper
• New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma

  2019cites this paper
• Molecular targets for tivantinib (ARQ 197) and vasculogenic mimicry in human melanoma cells

  2019cites this paper
• Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents

  2019cites this paper
• Selective Inhibition of Spindle Microtubules by a Tubulin-Binding Quinazoline Derivative

  2019cites this paper
• Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

  2019cites this paper
• Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

  2018cites this paper
• Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer

  2018cites this paper
• Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.

  2018cites this paper
• Phase I Trial of Anti‐MET Monoclonal Antibody in MET‐Overexpressed Refractory Cancer

  2018cites this paper
• Off-Target Based Drug Repurposing Using Systems Pharmacology

  2018influential citation
• Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

  2018cites this paper
• Ginkgolic acid suppresses the invasion of HepG2 cells via downregulation of HGF/c‑Met signaling.

  2018cites this paper
• C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview.

  2018cites this paper
• Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

  2018cites this paper
• Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology.

  2018cites this paper
• Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.

  2018cites this paper
• Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

  2018cites this paper
• ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo

  2018cites this paper
• Changes in cell morphology guide identification of tubulin as the off‐target for protein kinase inhibitors

  2018cites this paper
• First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors

  2018cites this paper
• Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

  2018cites this paper
• Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours

  2018cites this paper
• Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.

  2018cites this paper
• Non-kinase targets of protein kinase inhibitors

  2017cites this paper
• A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

  2017cites this paper
• Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR‐Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study

  2017cites this paper
• Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

  2017cites this paper
• C‐Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives

  2017cites this paper
• Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer

  2017cites this paper
• Tivantinib for the treatment of hepatocellular carcinoma

  2017influential citation
• Novel [1,2,4] Triazol [4,3-a] Pyridine Derivatives as Potential Selective c-Met Inhibitors with Improved Pharmacokinetic Properties.

  2017cites this paper
• Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

  2017cites this paper
• A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor

  2017cites this paper
• Recommendations for the Management of Rare Kidney Cancers.

  2017cites this paper